Bioavailability enhancement of an active substance by supercritical antisolvent precipitation

Viktor Majerik, Gérard Charbit, Elisabeth Badens, G. Horváth, László Szokonya, Nathalie Bosc, Eric Teillaud

Research output: Article

76 Citations (Scopus)

Abstract

Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercritical Antisolvent (SAS) process. Oxeglitazar was coprecipitated with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinilpyrrolidone (PVP K17) from six different solvents: ethanol (EtOH), tetrahydrofuran (THF), dichloromethane (DCM), chloroform (CHCl3), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixtures: EtOH/THF (50:50%, v/v) and EtOH/CHCl3 (50:50%, v/v). Formulations were compared in terms of particle morphology, crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissolution kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while experiments with PVP K17 resulted in quasi amorphous solid dispersions with high density and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissolution rate compared to raw drug and physical mixtures. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalJournal of Supercritical Fluids
Volume40
Issue number1
DOIs
Publication statusPublished - febr. 2007

Fingerprint

Poloxamer
bioavailability
Polyethylene glycols
formulations
augmentation
Dichloromethane
drugs
tetrahydrofuran
Dissolution
Methylene Chloride
dissolving
purity
Medical problems
Chlorine compounds
Dispersions
Pharmaceutical Preparations
Block copolymers
block copolymers
chloroform
Ethanol

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry
  • Materials Science (miscellaneous)
  • Physics and Astronomy (miscellaneous)

Cite this

Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. / Majerik, Viktor; Charbit, Gérard; Badens, Elisabeth; Horváth, G.; Szokonya, László; Bosc, Nathalie; Teillaud, Eric.

In: Journal of Supercritical Fluids, Vol. 40, No. 1, 02.2007, p. 101-110.

Research output: Article

Majerik, Viktor ; Charbit, Gérard ; Badens, Elisabeth ; Horváth, G. ; Szokonya, László ; Bosc, Nathalie ; Teillaud, Eric. / Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. In: Journal of Supercritical Fluids. 2007 ; Vol. 40, No. 1. pp. 101-110.
@article{624034ed4df04c33a28ebe5a87ce6c9d,
title = "Bioavailability enhancement of an active substance by supercritical antisolvent precipitation",
abstract = "Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercritical Antisolvent (SAS) process. Oxeglitazar was coprecipitated with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinilpyrrolidone (PVP K17) from six different solvents: ethanol (EtOH), tetrahydrofuran (THF), dichloromethane (DCM), chloroform (CHCl3), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixtures: EtOH/THF (50:50{\%}, v/v) and EtOH/CHCl3 (50:50{\%}, v/v). Formulations were compared in terms of particle morphology, crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissolution kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while experiments with PVP K17 resulted in quasi amorphous solid dispersions with high density and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissolution rate compared to raw drug and physical mixtures. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.",
keywords = "Bioavailability, Dissolution rate, Polymorphic purity, Poorly water soluble drug, Supercritical antisolvent",
author = "Viktor Majerik and G{\'e}rard Charbit and Elisabeth Badens and G. Horv{\'a}th and L{\'a}szl{\'o} Szokonya and Nathalie Bosc and Eric Teillaud",
year = "2007",
month = "2",
doi = "10.1016/j.supflu.2006.03.027",
language = "English",
volume = "40",
pages = "101--110",
journal = "Journal of Supercritical Fluids",
issn = "0896-8446",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Bioavailability enhancement of an active substance by supercritical antisolvent precipitation

AU - Majerik, Viktor

AU - Charbit, Gérard

AU - Badens, Elisabeth

AU - Horváth, G.

AU - Szokonya, László

AU - Bosc, Nathalie

AU - Teillaud, Eric

PY - 2007/2

Y1 - 2007/2

N2 - Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercritical Antisolvent (SAS) process. Oxeglitazar was coprecipitated with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinilpyrrolidone (PVP K17) from six different solvents: ethanol (EtOH), tetrahydrofuran (THF), dichloromethane (DCM), chloroform (CHCl3), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixtures: EtOH/THF (50:50%, v/v) and EtOH/CHCl3 (50:50%, v/v). Formulations were compared in terms of particle morphology, crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissolution kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while experiments with PVP K17 resulted in quasi amorphous solid dispersions with high density and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissolution rate compared to raw drug and physical mixtures. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.

AB - Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercritical Antisolvent (SAS) process. Oxeglitazar was coprecipitated with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinilpyrrolidone (PVP K17) from six different solvents: ethanol (EtOH), tetrahydrofuran (THF), dichloromethane (DCM), chloroform (CHCl3), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixtures: EtOH/THF (50:50%, v/v) and EtOH/CHCl3 (50:50%, v/v). Formulations were compared in terms of particle morphology, crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissolution kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while experiments with PVP K17 resulted in quasi amorphous solid dispersions with high density and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissolution rate compared to raw drug and physical mixtures. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.

KW - Bioavailability

KW - Dissolution rate

KW - Polymorphic purity

KW - Poorly water soluble drug

KW - Supercritical antisolvent

UR - http://www.scopus.com/inward/record.url?scp=33845484838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845484838&partnerID=8YFLogxK

U2 - 10.1016/j.supflu.2006.03.027

DO - 10.1016/j.supflu.2006.03.027

M3 - Article

AN - SCOPUS:33845484838

VL - 40

SP - 101

EP - 110

JO - Journal of Supercritical Fluids

JF - Journal of Supercritical Fluids

SN - 0896-8446

IS - 1

ER -